ライフサイエンスコーパス: gynecologic

1 rs) with stage I to IV lung (29%), GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or

2 Despite similar gynecologic age, body mass index, and type of sports par

3 for orthopedic surgery to 53.8% in urologic/gynecologic and 53.6% in other procedures.

4 HA membrane reduces adhesions in gynecologic and abdominal surgery but this is the first

5 and 2012 at an academic medical center with gynecologic and breast cancer centers.

6 ts (all P < .05); significant differences in gynecologic and cancer-specific concerns (P < .05) were

7 gnificantly improved depression and improved gynecologic and cancer-specific concerns at 4 months com

8 mmercial sex workers than in women attending gynecologic and family planning clinics.

9 oductive tract (FRT) is associated with many gynecologic and obstetric health complications.

10 Risks of combined gynecologic and plastic surgical procedures are not grea

11 primary site of cancer, including lung, GI, gynecologic, and brain; and comorbidities, including inf

12 ones on the progression of breast, prostate, gynecologic, and colorectal cancer.

13 o the abdominal cavity: abdominal, thoracic, gynecologic, and idiopathic.

14 General surgical, gynecologic, and orthopedic procedures composed 95.8% of

15 Sociodemographic, gynecologic, and periodontal variables were gathered for

16 ic body CT has become invaluable to medical, gynecologic, and radiation oncologists.

17 (general surgery, orthopedic, neurosurgical, gynecologic, and urologic) in adult patients with low su

18 ignant ovarian ascites and from nonmalignant gynecologic ascites.

19 ent verification and dosimetric planning for gynecologic brachytherapy.

20 ent verification and dosimetric planning for gynecologic brachytherapy.

21 gested that women with previous diagnoses of gynecologic cancer (cervical, endometrial, or ovarian) h

22 ; 95% CI, 0.30 to 1.22) and BRCA2-associated gynecologic cancer (HR = 0.00; 95% CI, not estimable) wa

23 mary diagnosis of breast (stage 0 to III) or gynecologic cancer (International Federation of Gynecolo

24 Ovarian cancer is the second most common gynecologic cancer among women and the second leading ca

25 recruited: breast, prostate, colorectal, and gynecologic cancer and non-Hodgkin's lymphoma.

26 impact when PET is utilized in patients with gynecologic cancer are primarily limited to patients wit

27 t may prove to be a mainstay in personalized gynecologic cancer care.

28 diated metabolic coupling between O-ASCs and gynecologic cancer cells in which O-ASCs support NO home

29 cer Cell Line Encyclopedia databank, 68% are gynecologic cancer cells.

30 controlled trial was undertaken within eight gynecologic cancer centers in the Netherlands.

31 al cancer in women with previously diagnosed gynecologic cancer compared with women without gynecolog

32 e, US Department of Defense, Sanofi-Aventis, Gynecologic Cancer Foundation, Marcus Foundation, and th

33 Endometrial cancer is the most common gynecologic cancer in the United States and its incidenc

34 Endometrial cancer is the most common female gynecologic cancer in the United States.

35 Cervical cancer is the third most common gynecologic cancer in the United States.

36 Ovarian cancer is the most lethal type of gynecologic cancer in the Western world.

37 ctive in decreasing risks of both breast and gynecologic cancer in women with BRCA mutations.

38 lactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutation

39 Secondary end points included response by Gynecologic Cancer Intergroup criteria, duration of ORR,

40 Response was evaluated by RECIST v1.1 and Gynecologic Cancer Intergroup criteria.

41 ial 178 patients (n = 288) and compared with Gynecologic Cancer Intergroup criterion.

42 terval between surgery and chemotherapy, and Gynecologic Cancer InterGroup group.

43 In the Gynecologic Cancer Intergroup International Collaboratio

44 ic minority, low-income women with breast or gynecologic cancer is prevalent and is correlated with p

45 The omission of DWI for staging or restaging gynecologic cancer may significantly reduce examination

46 for subsequent breast cancer or BRCA-related gynecologic cancer of 0.25 (95 percent confidence interv

47 dity; mortality; diagnostic accuracy for any gynecologic cancer or condition except cervical cancer,

48 er (30% of breast cancer patients and 17% of gynecologic cancer patients).

49 ed with an 85% reduction in BRCA1-associated gynecologic cancer risk (hazard ratio [HR] = 0.15; 95% C

50 ely adopted as a key component of breast and gynecologic cancer risk-reduction for women with BRCA1 a

51 nical guidelines, all young individuals with gynecologic cancer should be counseled about the availab

52 dence ratios (SIRs) were calculated for each gynecologic cancer site and for subgroups to represent t

53 As the number of gynecologic cancer survivors grows, there is an increase

54 ent studies to help the clinician caring for gynecologic cancer survivors in recognizing and treating

55 me to diagnosis of breast or BRCA-associated gynecologic cancer was analyzed using a Cox proportional

56 The time to breast cancer or BRCA-related gynecologic cancer was longer in the salpingo-oophorecto

57 Rates of the most common gynecologic cancer, endometrioid adenocarcinoma (EAC), c

58 an cancer is the leading cause of death from gynecologic cancer, in part because of the lack of effec

59 % over a lifetime, but it is the most deadly gynecologic cancer, in part due to lack of diagnostic ma

60 ovarian cancer is the most frequent cause of gynecologic cancer-related mortality in women, and progn

61 an cancer is the leading cause of death from gynecologic cancer.

62 among women who are diagnosed with breast or gynecologic cancer.

63 for prevention of breast and BRCA-associated gynecologic cancer.

64 infertility as a sequel to the treatment of gynecologic cancer.

65 e the risk of breast cancer and BRCA-related gynecologic cancer.

66 necologic cancer compared with women without gynecologic cancer.

67 colorectal cancer across subgroups with each gynecologic cancer.

68 lementary roles in the care of patients with gynecologic cancer.

69 se (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).

70 ociated with an increased risk of breast and gynecologic cancers (OR = 4.37, 95% CI: 2.68-7.13, P < 0

71 vity on survival or recurrence in breast and gynecologic cancers are not yet established, and randomi

72 dy to determine the reduction in the risk of gynecologic cancers associated with prophylactic hystere

73 Tumors from patients with advanced stage gynecologic cancers decorated with CD80-SA elicited pote

74 ts of continuous combined hormone therapy on gynecologic cancers have not been investigated previousl

75 ian cancer is the first in mortalities among gynecologic cancers in the United States, often due to l

76 ntinues to carry the highest mortality among gynecologic cancers in the western world.

77 of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations.

78 inoma is the most common cause of death from gynecologic cancers largely due to advanced, relapsed an

79 tection conferred by RRSO against breast and gynecologic cancers may differ between carriers of BRCA1

80 PET is used in patients with other gynecologic cancers such as endometrial cancer, uterine

81 The incidence of other gynecologic cancers was low and did not differ by random

82 ctal cancer, retroperitoneal sarcoma, select gynecologic cancers, and other malignancies.

83 could contribute to tumor immune evasion in gynecologic cancers, especially in endometrial cancer.

84 involvement of c-fms and its ligand CSF-1 in gynecologic cancers, such as that of the uterus and the

85 s of breast cancer, non-Hodgkin lymphoma, or gynecologic cancers.

86 GMT promoter hypermethylation and breast and gynecologic cancers.

87 and SMAD3 transcription and tumor growth in gynecologic cancers.

88 al activity, or diet with prognosis in other gynecologic cancers.

89 ant means for immunologic targeting of human gynecologic cancers.

90 of MGMT promoter and the risk of breast and gynecologic cancers.

91 (MGMT) remains controversial for breast and gynecologic cancers.

92 ses of cervical cancer, and 7 cases of other gynecologic cancers.

93 patients with advanced endometrial and other gynecologic cancers.

94 correct the critical genetic defects seen in gynecologic cancers.

95 ted and efficacious treatment for women with gynecologic cancers.

96 atment of persistent or recurrent metastatic gynecologic cancers.

97 UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EM

98 Referral should be sought for specialized gynecologic care and for issues related to HIV itself, s

99 ington State women who presented for routine gynecologic care from 1997 to 2001 was conducted.

100 esia developments well applied to ambulatory gynecologic cases.

101 23 to 42 years) was undertaken in a private gynecologic center between weeks 32 and 35 of pregnancy

102 colaou smear, and/or women seeking a routine gynecologic checkup.

103 iated with increased risk of obstetrical and gynecologic complications and acquisition of sexually tr

104 ptoms are easily recognizable, obstetric and gynecologic complications continue to increase in number

105 ociated with a wide variety of obstetric and gynecologic complications including serious infections a

106 TC benefits mood and QOL cancer-specific and gynecologic concerns for a multiethnic underserved popul

107 o are not at increased risk for any specific gynecologic condition.

108 ndiceal gastrointestinal conditions (46.0%), gynecologic conditions (21.6%), genitourinary conditions

109 anced-stage EOC from women with nonmalignant gynecologic conditions and may be complementary to CA125

110 independent sera of women with nonmalignant gynecologic conditions and those with advanced-stage or

111 arms of the screening pelvic examination for gynecologic conditions for the US Preventive Services Ta

112 robotically assisted hysterectomy for benign gynecologic conditions has been reported, little is know

113 early detection and treatment of a range of gynecologic conditions in asymptomatic, nonpregnant adul

114 rce (USPSTF) recommendation on screening for gynecologic conditions with pelvic examination for condi

115 Endometriosis is a prevalent gynecologic disease associated with systemic chronic inf

116 d with healthy controls or women with benign gynecologic diseases.

117 14 patients having other benign or malignant gynecologic diseases.

118 robotically assisted hysterectomy for benign gynecologic disorders increased substantially.

119 onography in the diagnosis and management of gynecologic disorders of the pediatric pelvis, including

120 Gynecologic evaluation included Nugent score and Amsel c

121 Gynecologic evaluation included Nugent score assessment,

122 nal discharge, STI exposure, or preventative gynecologic examination were evaluated for Trichomonas i

123 e CD4 lymphocyte count, HIV-1 RNA level, and gynecologic examination with Papanicolaou smear.

124 neficial association with patient receipt of gynecologic examinations and Papanicolaou smears, choles

125 tamoxifen therapy should have routine annual gynecologic examinations and receive endometrial samplin

126 Gynecologic examinations and sexual quality-of-life ques

127 g and Papanicolaou testing were collected at gynecologic examinations every four months.

128 Triannual gynecologic examinations included cervical and vulvovagi

129 Forty-nine of the participants underwent gynecologic examinations with vaginal smears for determi

130 Regular gynecologic follow-up is required in uremic women to gua

131 Patients receiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertia

132 men attending clinic for routine nonreferral gynecologic health care.

133 arcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as mal

134 ed presentation and atypical microbiology of gynecologic infection in an organ transplant recipient.

135 A gynecologic infection is the most common symptom that le

136 1.7, 95% CI: 1.1, 2.6), and prior history of gynecologic infection/disease (OR = 2.6, 95% CI: 1.2, 5.

137 garette smoking, aspirin use, and history of gynecologic infection/disease.

138 Local anesthetic use in gynecologic laparoscopy appears to improve postoperative

139 he highest prevalences were in patients with gynecologic malignancies (two of 13, 15%) and in those w

140 um (HOSE) is the leading cause of death from gynecologic malignancies among American women.

141 an cancer is the leading cause of death from gynecologic malignancies amongst American women.

142 ed to validate the use of robotic surgery in gynecologic malignancies and to compare its outcomes to

143 tion of Gynecology and Obstetrics staging of gynecologic malignancies are also described in detail, h

144 chniques used in evaluation of patients with gynecologic malignancies are described, including both a

145 Eighty patients with gynecologic malignancies beginning standard chemotherapy

146 Current therapy of gynecologic malignancies consists of platinum-containing

147 erous adenocarcinomas of the ovary and other gynecologic malignancies that is distinguished by highly

148 Patients with gynecologic malignancies treated at the Cleveland Clinic

149 types were similar in both groups, but fewer gynecologic malignancies were noted in GCA patients (OR

150 ET imaging is underutilized in patients with gynecologic malignancies, and its role in current clinic

151 ins the leading cause of death in women with gynecologic malignancies, despite surgical advances and

152 veral treatment modalities are used to treat gynecologic malignancies, including surgery, radiotherap

153 radical procedures and decrease morbidity in gynecologic malignancies, much effort is being focused o

154 osis of ovarian cancer, the deadliest of the gynecologic malignancies, reflects major limitations ass

155 the p53 and BRCA1 tumor suppressor genes in gynecologic malignancies, we generated mice in which p53

156 g recurrent tumor after treatment of various gynecologic malignancies.

157 e use of robotic surgery in the treatment of gynecologic malignancies.

158 use of robotic surgery in the management of gynecologic malignancies.

159 Ovarian cancer is the most lethal of the gynecologic malignancies.

160 n cancer is the leading cause of death among gynecologic malignancies.

161 the-art use of PET imaging for patients with gynecologic malignancies.

162 e highest mortality rate among patients with gynecologic malignancies.

163 ct management and prognosis of patients with gynecologic malignancies.

164 with excellent survival compared with other gynecologic malignancies.

165 cation of many of these genetic mutations in gynecologic malignancies.

166 eatment options and therapy in patients with gynecologic malignancies.

167 Ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of ca

168 Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth most common cause o

169 Endometrial cancer is the most common gynecologic malignancy and the fourth most common malign

170 Ovarian cancer is a deadly gynecologic malignancy for which novel biomarkers and th

171 Although many advances in the management of gynecologic malignancy have been achieved over the last

172 Ovarian cancer is the most lethal gynecologic malignancy in both African-American and whit

173 Endometrial cancer is the most common gynecologic malignancy in the United States and the most

174 Endometrial cancer is the most common gynecologic malignancy in the United States, with 37,400

175 ovarian cancer (EOC) remains the most lethal gynecologic malignancy in the United States.

176 Ovarian cancer remains the most lethal gynecologic malignancy in the United States.

177 ndometrial adenocarcinoma is the most common gynecologic malignancy in the United States.

178 Although ovarian cancer is the most lethal gynecologic malignancy in women, little is known about h

179 Ovarian cancer is a lethal gynecologic malignancy that may benefit from new therapi

180 Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate.

181 Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of mere

182 n and the second leading cause of death from gynecologic malignancy worldwide.

183 Endometrial cancer is the most common gynecologic malignancy, and its incidence and associated

184 Ovarian cancer, the most deadly gynecologic malignancy, is often diagnosed late and at t

185 ovarian cancer (EOC) remains the most lethal gynecologic malignancy, underscoring the need for better

186 cer (EOC) is the leading cause of death from gynecologic malignancy, with high mortality attributable

187 ovarian cancer is the most frequent cause of gynecologic malignancy-related mortality in women.

188 ctor for endometrial cancer, the most common gynecologic malignancy.

189 lial ovarian cancer (EOC) is the most lethal gynecologic malignancy.

190 ate the therapeutic potential of SK1 in this gynecologic malignancy.

191 lial ovarian cancer (EOC) is the most lethal gynecologic malignancy.

192 Epithelial ovarian cancer is the most lethal gynecologic malignancy; it is highly aggressive and caus

193 e ovarian serous carcinomas, the most lethal gynecologic neoplastic disease in women.

194 The importance of associated urologic, gynecologic, neurologic, and orthopedic malformations ha

195 030 enrolled patients who underwent general, gynecologic, neurologic, or cardiothoracic surgery, 3864

196 guidelines for optimizing the management of gynecologic/obstetric events in female patients with HAE

197 number of publications on the management of gynecologic/obstetric events in female patients with her

198 lege of Surgeons hospital and treatment by a gynecologic oncologist increased the likelihood of recei

199 lial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy.

200 administered by medical oncologists (MOs) or gynecologic oncologists (GOs).

201 Of 18,338 women, 21.4% received care from gynecologic oncologists (group A) while 78.6% were treat

202 Reimbursement for gynecologic oncologists can be categorized into three ar

203 necology has recommendations for referral to gynecologic oncologists for the treatment of endometrial

204 Care provided by gynecologic oncologists improved the survival of those w

205 re, we propose to determine the influence of gynecologic oncologists on the treatment and survival of

206 , early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic fact

207 Patients with endometrial cancer treated by gynecologic oncologists were more likely to undergo stag

208 medical oncologists, radiation oncologists, gynecologic oncologists, urologists, hematologists, pedi

209 ly considered the major source of income for gynecologic oncologists.

210 eated by medical oncologists, urologists, or gynecologic oncologists.

211 The Society of Gynecologic Oncology and the American Society of Clinica

212 went prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital.

213 Laparoscopy at present has a limited role in gynecologic oncology but may be useful for prophylactic

214 ness analysis compared the three arms of the Gynecologic Oncology Group (GOG) 218 study (paclitaxel p

215 erim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial.

216 In this regard, the Gynecologic Oncology Group (GOG) and other organizations

217 ted for response and toxicity using standard Gynecologic Oncology Group (GOG) and World Health Organi

218 The Gynecologic Oncology Group (GOG) conducted a phase II tr

219 -FU) and cisplatin (CF) was activated by the Gynecologic Oncology Group (GOG) for the treatment of pa

220 ) gynecologic tissue bank (n = 570) and from Gynecologic Oncology Group (GOG) phase III clinical tria

221 ocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172

222 Patients entered on Gynecologic Oncology Group (GOG) Protocol 179 were expec

223 e from women participating in representative Gynecologic Oncology Group (GOG) protocols.

224 A Gynecologic Oncology Group (GOG) randomized phase III tr

225 mous cell carcinoma of the cervix in a prior Gynecologic Oncology Group (GOG) trial, a phase II study

226 5 patients with EOC or PPC enrolled onto the Gynecologic Oncology Group 182 study.

227 randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute

228 The Gynecologic Oncology Group conducted a phase II evaluati

229 The Gynecologic Oncology Group conducted a randomized, phase

230 ted for response and toxicity using standard Gynecologic Oncology Group criteria.

231 College of Radiology Imaging Network and the Gynecologic Oncology Group from March 2000 to November 2

232 The Gynecologic Oncology Group has initiated a pilot phase I

233 mber 2011, 55 patients were enrolled by five Gynecologic Oncology Group member institutions; of those

234 the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire a

235 The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire w

236 cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of at leas

237 merican College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial wa

238 an cancer specimens from patients treated on Gynecologic Oncology Group protocol 111.

239 analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the

240 Data from Gynecologic Oncology Group protocols 114 and 172 were re

241 ith a BRCA mutation and 2 additional groups (Gynecologic Oncology Group protocols 52 and 111) with ov

242 tumors from 125 patients participating in a Gynecologic Oncology Group randomized phase III treatmen

243 In two large Gynecologic Oncology Group studies of patients with adva

244 can College of Radiology Imaging Network and Gynecologic Oncology Group study of 172 women with biops

245 ve Ovarian Neoplasm Group trial (ICON7), the Gynecologic Oncology Group trial (GOG218), OCEANS and AU

246 ested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients (n = 288)

247 For the Gynecologic Oncology Group, we conducted a trial to dete

248 On behalf of the Gynecologic Oncology Group, we performed a randomized tr

249 unctional Assessment of Cancer Therapy Scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)

250 rted Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item senso

251 the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity, may be used in

252 omized phase III trial conducted through the Gynecologic Oncology Group.

253 The Society of Gynecologic Oncology guidelines categorize CA-125 testin

254 , the University of California San Francisco Gynecologic Oncology Program instituted a surgical-patho

255 al criteria (Amsterdam, Bethesda, Society of Gynecologic Oncology, ANECS).

256 iology, obstetric, interventional radiology, gynecologic oncology, blood bank, and specialized surgic

257 ined a strong foothold in urologic oncology, gynecologic oncology, cardiothoracic surgery and now in

258 y convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokin

259 ternational experts in genetics, medical and gynecologic oncology, clinical psychology, epidemiology,

260 In current gynecologic oncology, HIFU is used clinically in the tre

261 of prospective trials validating its use in gynecologic oncology.

262 eural disease antigens that are expressed by gynecologic or lung tumors and by neurons.

263 (12.1%), lymph nodes (10.9%), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%),

264 ancies, and 27 with benign lesions involving gynecologic organs.

265 the prevention of breast and BRCA-associated gynecologic (ovarian, fallopian tube or primary peritone

266 time risk of both breast and BRCA-associated gynecologic (ovarian, fallopian tube, and primary perito

267 All cases were reviewed by a gynecologic pathologist, and clinical information was ab

268 icians and Gynecologists (ACOG) Committee on Gynecologic Practice had previously issued a committee o

269 al of the IUD, or the presence or absence of gynecologic problems related to its use.

270 women may delay seeking health services for gynecologic problems resulting in hysterectomy as the la

271 used extensively in the evaluation of common gynecologic problems, such as menorrhagia and postmenopa

272 All patients undergoing gastrointestinal or gynecologic procedures from January 1, 2005 to June 1, 2

273 Several gynecologic procedures including tubal ligation, oophore

274 ding colorectal, arthroplasty, vascular, and gynecologic procedures.

275 , 5 to 67 ng/mL) for individuals with benign gynecologic processes (P = NS).

276 gh-risk individuals, 33 patients with benign gynecologic processes, and 50 preoperative patients subs

277 ribution to the banked clinical successes in gynecologic radiation oncology.

278 RECENT FINDINGS: Small-cell carcinomas of gynecologic sites are rare and carry a poor prognosis.

279 erican Medical Association, and the American Gynecologic Society.

280 e with good performance status presented for gynecologic surgery for a benign condition.

281 The benefit of prophylactic gynecologic surgery for women with this syndrome has bee

282 esia care for patients undergoing ambulatory gynecologic surgery has improved incrementally over the

283 tatus was determined from menstrual history, gynecologic surgery, hormone replacement therapy, follic

284 vascular surgery, and 10.7% (36 of 336) for gynecologic surgery.

285 f women are taking tamoxifen, a strategy for gynecologic surveillance is needed.

286 Although there is some increase in gynecologic symptoms and diminution in sexual pleasure,

287 of the increased frequency of vasomotor and gynecologic symptoms and problems of sexual functioning

288 the strongest effects on physical health and gynecologic symptoms followed similar patterns.

289 62; 95% CI, 0.42 to 0.91; P = .016), whereas gynecologic symptoms were significant only in the tamoxi

290 group and was associated with vasomotor and gynecologic symptoms.

291 ified from the University of Washington (UW) gynecologic tissue bank (n = 570) and from Gynecologic O

292 POSE OF REVIEW: Small-cell carcinomas of the gynecologic tract are aggressive malignancies that can b

293 The majority of small-cell tumors of the gynecologic tract will require systemic chemotherapy wit

294 as are reported to be the most common benign gynecologic tumors affecting premenopausal women, and th

295 nd 50 JAK1 truncating mutations in 36 of 635 gynecologic tumors in the Total Cancer Care(R) (TCC(R))

296 rols with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian c

297 rian cancer has the highest mortality of all gynecologic tumors, and there is an urgent need for spec

298 er as it is the leading cause of death among gynecologic tumors.

299 Excluding procedures for gynecologic/urologic malignancies, the proportion of pro

300 oups (17 general surgical, 6 vascular, and 1 gynecologic) were examined.